Cogent Biosciences (COGT) risk factors, FY2024 10-K

Risks Related to the Discovery and Development of Our Drug Candidates

1. 01Our business is highly dependent on the success of our bezuclastinib program and our ability to discover and develop additional product candidates. We may not be successful in our efforts to develop bezuclastinib or expand our pipeline of drug candidates
2. 02If unacceptable side effects are identified during the development of our drug candidates, we may need to abandon or limit such development
3. 03We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively
4. 04If difficulties arise enrolling patients in our clinical trials, clinical development activities could be delayed or otherwise adversely affected
5. 05Clinical trials are expensive, time-consuming, and difficult to design and implement
6. 06Since the number of patients that we have dosed to date in our clinical trials is small, the results from such clinical trials may be less reliable than results achieved in larger clinical trials
7. 07We may choose not to develop a potential product candidate, or we may suspend, deprioritize or terminate one or more discovery programs or preclinical or clinical product candidates or programs
8. 08We may form or seek collaborations or strategic alliances or enter into additional licensing arrangements in the future, but we may not realize any resulting benefits
9. 09We may not be able to file investigational new drug applications (“IND”s) or IND amendments or clinical trial authorization applications (“CTA”s) to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA or other regulatory authorities may not permit us to proceed
10. 10Our updated bezuclastinib formulation is unproven and may not work as intended in clinical trials
11. 11The commercial success of any future approved drugs, including bezuclastinib, will depend upon the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community
12. 12A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business
13. 13Information obtained from expanded access studies may not reliably predict the efficacy of our future product candidates in company-sponsored clinical trials and may lead to adverse events that could limit approval

Risks Related to Our Reliance on Third Parties

1. 14The third parties upon whom we rely for the supply of the API and drug product used in bezuclastinib are our sole source of supply, and the loss of any of these suppliers could significantly harm our business

Risks Related to Regulatory Approval of Our Drug Candidates and Other Legal Compliance Matters

1. 15The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates
2. 16Regulatory authorities, including the FDA, may disagree with our regulatory plan and we may fail to obtain regulatory approval of our product candidates
3. 17Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions
4. 18The impact of healthcare legislation and other changes in the healthcare industry and in healthcare spending on us is currently unknown, and may adversely affect our business model
5. 19Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
6. 20We face potential liability related to the privacy of health information we obtain from clinical trials sponsored by us
7. 21If we are unable to successfully develop companion diagnostic tests for our drug candidates that require such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these drug candidates
8. 22Pharmaceutical and biological product marketing is subject to substantial regulation in the U.S. and any failure by us or our commercial and collaborative partners to comply with applicable statutes or regulations can adversely affect our business

Risks Related to Our Intellectual Property

1. 23If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our market
2. 24We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business
3. 25We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses
4. 26Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts
5. 27We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful
6. 28Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO
7. 29Patent terms may be inadequate to protect our competitive position on our product candidates and any future products for an adequate amount of time
8. 30Changes to patent law in the United States and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates and future products
9. 31We may not be able to seek or obtain patent protection throughout the world or enforce such patent protection once obtained
10. 32If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our trademarks of interest and our business may be adversely affected

Risks Related to Employee Matters and Managing Growth

1. 33We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy
2. 34During the past two years we increased our headcount from 138 to 205 full time employees through the expansion of our research, development, manufacturing and G&A infrastructure. We need to continue to recruit, train and retain qualified personnel to support our growth and we may be unable to do so effectively
3. 35Our business and operations could suffer in the event of system failures or unauthorized or inappropriate use of or access to our systems

Risks Related to Our Financial Position and Need for Additional Capital

1. 36We will require substantial additional funding. If we fail to obtain additional financing when needed, or on attractive terms, we may be unable to complete the development and commercialization of our product candidates
2. 37We have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future
3. 38our ability to avoid third-party patent interference, intellectual property challenges or intellectual property infringement claims
4. 39Our ability to use net operating losses and tax credit carryforwards to offset future taxable income may be subject to certain limitations
5. 40We may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition

Risks Related to Ownership of our Common Stock

1. 41The price of our stock may be volatile, and you could lose all or part of your investment
2. 42Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant influence over matters subject to stockholder approval
3. 43An active trading market for our common stock may not be sustained
4. 44Future sales and issuances of our common stock or rights to purchase common stock could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall
5. 45Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control, which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management